- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Design Therapeutics Inc (DSGN)
Design Therapeutics Inc stock price live, this page displays NASDAQ DSGN stock exchange data. View the DSGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Design Therapeutics Inc real time stock price chart below.
What Is the Design Therapeutics Inc Stock Price Today?
The Design Therapeutics Inc stock price today is 12.340.
What Is the Stock Symbol for Design Therapeutics Inc?
The stock symbol for Design Therapeutics Inc is "DSGN."
What Stock Exchange Does Design Therapeutics Inc Trade On?
Design Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Design Therapeutics Inc a Good Stock to Buy?
Determining whether Design Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DSGN quote. (ISIN: US25056L1035)
What Is the Design Therapeutics Inc Stock Price Today?
The Design Therapeutics Inc stock price today is 12.340.
What Is the Stock Symbol for Design Therapeutics Inc?
The stock symbol for Design Therapeutics Inc is "DSGN."
What Stock Exchange Does Design Therapeutics Inc Trade On?
Design Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Design Therapeutics Inc a Good Stock to Buy?
Determining whether Design Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DSGN quote. (ISIN: US25056L1035)
NASDAQ
Currency in USD
12.340
+0.320(+2.66%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.045
12.350
52 wk Range
3.760
17.250
Earnings results expected in 11 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.04512.350
52 wk Range
3.76017.250
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DSGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
21.000
Upside
+70.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Form 4 Design Therapeutics Inc For: 11 June- Investing.com
Form 13G Design Therapeutics For: 9 June- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.000
(+70.18% Upside)
Design Therapeutics Inc SWOT Analysis
GeneTAC Innovation | Design Therapeutics pioneers geneTAC technology, combining ASO and small molecule approaches to target genetic disorders with high unmet needs |
Pipeline Progress | Explore the company's lead assets in Friedreich's ataxia and Fuchs corneal dystrophy, crucial for near-term prospects and platform validation |
Market Potential | Analyst targets range from $4 to $12 per share, reflecting diverse views on Design Therapeutics' growth potential in the genetic disorder treatment market |
Challenges Ahead | Learn about the early-stage nature of all programs and the potential impact on investor confidence and future funding needs |
Design Therapeutics Inc Earnings Call Summary for Q1/2026
- Design Therapeutics posted Q1 2026 EPS of -$0.29, beating consensus estimate of -$0.32 by 9.38%; no revenue disclosed as company remains pre-revenue.
- Stock held steady at $12.81 in premarket trading, near 52-week high of $13.54; InvestingPro rates financial health as 'GOOD' but flags overvaluation.
- Company focuses on RESTORE-FA trial for Friedreich's Ataxia, with pivotal data expected in second half of 2026 to establish clinical proof of concept.
- CEO Pratik Shah emphasized biomarker-driven development strategy, targeting single surrogate biomarker to predict clinical benefit for regulatory approval.
- Analyst price targets range $12-$18; key risks include uncertain cash runway, competitive pressures, and regulatory challenges for accelerated approval pathway.
Last Updated: 04/29/2026, 04:42 PM
Read Full TranscriptEarnings
Latest Release
Apr 28, 2026
EPS / Forecast
-0.29 / -0.32
Revenue / Forecast
-- / --
Compare DSGN to Peers and Sector
Metrics to compare | DSGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDSGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −1.9x | −0.3x | |
PEG Ratio | 0.53 | −0.01 | 0.00 | |
Price/Book | 3.4x | 2.3x | 2.6x | |
Price / LTM Sales | - | 41.1x | 2.9x | |
Upside (Analyst Target) | 74.7% | 87.5% | 56.7% | |
Fair Value Upside | Unlock | 3.1% | 10.2% | Unlock |
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Design Therapeutics (DSGN) Stock Price Today?
The Design Therapeutics stock price today is 12.340 USD.
What Stock Exchange Does Design Therapeutics Trade On?
Design Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Design Therapeutics?
The stock symbol for Design Therapeutics is "DSGN."
What Is the Design Therapeutics Market Cap?
As of today, Design Therapeutics market cap is 760.410M USD.
What Is Design Therapeutics's Earnings Per Share (TTM)?
The Design Therapeutics EPS (TTM) is -1.192.
When Is the Next Design Therapeutics Earnings Date?
Design Therapeutics will release its next earnings report on Aug 10, 2026.
From a Technical Analysis Perspective, Is DSGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Design Therapeutics Stock Split?
Design Therapeutics has split 0 times.
How Many Employees Does Design Therapeutics Have?
Design Therapeutics has 54 employees.
What is the current trading status of Design Therapeutics (DSGN)?
As of Jul 30, 2026, Design Therapeutics (DSGN) is trading at a price of 12.340 USD, with a previous close of 12.020 USD. The stock has fluctuated within a day range of 12.045 USD to 12.350 USD, while its 52-week range spans from 3.760 USD to 17.250 USD.
What Is Design Therapeutics (DSGN) Price Target According to Analysts?
The average 12-month price target for Design Therapeutics is 21.000 USD, with a high estimate of 22 USD and a low estimate of 20 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +70.18% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.